Get all your news in one place.
100’s of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
World
James Skinner

Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers

Roche (RHHBY) shares fell the most in nearly two months Wednesday after the Swiss drugmaker's Tecentriq oncology treatment fell short in a key clinical trial for use as a bladder cancer treatment.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.